Kwality Pharmaceuticals' Q4 FY 2025-26 Quarterly Results

Result Summary

• Kwality Pharmaceuticals Ltd reported a 27.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 35.8%.
• Its expenses for the quarter were up by 25.5% QoQ and 29.9% YoY.
• The net profit increased 58.1% QoQ and increased 74.7% YoY.
• The earnings per share (EPS) of Kwality Pharmaceuticals Ltd stood at 24.39 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Kwality Pharmaceuticals Ltd is a company engaged in the production and distribution of pharmaceutical products. The company operates within the pharmaceutical industry, focusing on the development and manufacturing of a wide range of medicinal products. As of the latest available information, specific recent major developments within Kwality Pharmaceuticals Ltd are not available. The company continues to operate in a highly regulated industry that demands strict compliance with health and safety standards. More detailed insights into its strategic initiatives, product launches, or market expansions are not provided in the available data.

Revenue

The financial data for Kwality Pharmaceuticals Ltd indicates a significant increase in total income in the fourth quarter of the fiscal year 2026 (Q4FY26). Total income reached ₹158.17 crores, representing a 27.6% increase quarter-over-quarter (QoQ) from Q3FY26, which was ₹123.97 crores. Year-over-year (YoY), the total income grew by 35.8% from Q4FY25, where it stood at ₹116.44 crores. This growth in total income suggests an upward trend in the company's revenue generation capabilities over the relevant periods.

Profitability

The profitability metrics for Kwality Pharmaceuticals Ltd show notable improvements. Profit Before Tax (PBT) in Q4FY26 was ₹31.67 crores, marking a 41.7% increase QoQ from ₹22.35 crores in Q3FY26 and a 66.1% increase YoY from ₹19.07 crores in Q4FY25. Profit After Tax (PAT) also rose significantly to ₹25.29 crores in Q4FY26, up 58.1% QoQ from ₹16.00 crores in Q3FY26, and 74.7% YoY from ₹14.48 crores in Q4FY25. These figures indicate a strong profitability performance, further corroborated by the Earnings Per Share (EPS) that increased to ₹24.39 in Q4FY26 from ₹15.42 in Q3FY26, reflecting a 58.2% QoQ growth, and a 74.8% YoY rise from ₹13.95 in Q4FY25.

Operating Metrics

In terms of operating expenses, Kwality Pharmaceuticals Ltd reported a total expense of ₹126.50 crores in Q4FY26, which is an increase of 25.5% QoQ from ₹100.79 crores in Q3FY26 and a 29.9% increase YoY from ₹97.37 crores in Q4FY25. The tax expenses remained relatively stable at ₹6.36 crores in Q4FY26 compared to ₹6.35 crores in Q3FY26, showing a minimal increase of 0.2%, and a YoY increase of 38.6% from ₹4.59 crores in Q4FY25. These metrics highlight the company's operating dynamics, reflecting both cost management and growth in operational scale over the periods considered.